Santhera Pharmaceuticals Holding AG (SANN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Santhera Pharmaceuticals Holding AG (SANN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10158
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Santhera Pharmaceuticals Holding AG (Santhera) develops and commercializes novel pharmaceutical products indicated for patients with mitochondrial and neuromuscular diseases. It specifically focuses in the area of neuromuscular and neuro-ophthalmological conditions. The company’s lead product candidate, Raxone (idebenone), is developed for the treatment of Leber’s hereditary optic neuropathy (LHON). Raxone is also investigated for other diseases such as Duchenne muscular dystrophy and primary progressive multiple sclerosis. Santhera’s pipeline also includes other compounds, namely, omigapil for congenital muscular dystrophies. It operates along with its subsidiaries located in Switzerland, Germany, Canada, Finland and the US. Santhera is headquartered in Pratteln, Switzerland.

Santhera Pharmaceuticals Holding AG (SANN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Santhera Pharma Enters into Distribution Agreement with Pharmathen Pharma 10
Licensing Agreements 11
Santhera Pharma Enters into Licensing Agreement with Polyphor 11
Equity Offering 12
Santhera Pharma Raises USD53.3 Million in Private Placement of Shares 12
Santhera Pharma Raises USD28 Million through Private Placement of Shares 13
Santhera Pharma Raises USD15 Million in Public Offering of Shares 14
Santhera Pharma Completes Private Placement Of Shares For US$1 Million 15
Santhera Pharma Announces Private Placement Of Units For US$11 Million 16
Debt Offering 17
Santhera Pharma Raises USD60.2 Million in Public Offering of 5% Bonds Due 2022 17
Santhera Pharmaceuticals Holding AG – Key Competitors 18
Santhera Pharmaceuticals Holding AG – Key Employees 19
Santhera Pharmaceuticals Holding AG – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Financial Announcements 21
Sep 04, 2018: Santhera Announces Financial Results for the First Half-Year 2018 and Updates on Operational Progress and Growth Strategy 21
Mar 20, 2018: Santhera Reports Solid Top-line Growth in 2017 and Reiterates its Strategy to Obtain Approval for Idebenone in Duchenne Muscular Dystrophy 23
Jan 29, 2018: Santhera Reports Preliminary Key Financial Figures for 2017 and Provides Corporate Update 25
Sep 05, 2017: Santhera Announces Financial Results for the First Half-Year 2017 and Reports Commercial and Development Progress 27
Mar 07, 2017: Santhera Delivered Solid Performance in 2016 and Advances All Programs 28
Jan 26, 2017: Santhera Reports Preliminary Key Financial Figures For 2016 And Provides Corporate Update 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Santhera Pharmaceuticals Holding AG, Deals By Therapy Area, 2012 to YTD 2018 8
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Santhera Pharma Enters into Distribution Agreement with Pharmathen Pharma 10
Santhera Pharma Enters into Licensing Agreement with Polyphor 11
Santhera Pharma Raises USD53.3 Million in Private Placement of Shares 12
Santhera Pharma Raises USD28 Million through Private Placement of Shares 13
Santhera Pharma Raises USD15 Million in Public Offering of Shares 14
Santhera Pharma Completes Private Placement Of Shares For US$1 Million 15
Santhera Pharma Announces Private Placement Of Units For US$11 Million 16
Santhera Pharma Raises USD60.2 Million in Public Offering of 5% Bonds Due 2022 17
Santhera Pharmaceuticals Holding AG, Key Competitors 18
Santhera Pharmaceuticals Holding AG, Key Employees 19
Santhera Pharmaceuticals Holding AG, Subsidiaries 20

List of Figures
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Santhera Pharmaceuticals Holding AG (SANN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • The Wistar Institute:製薬・医療:M&Aディール及び事業提携情報
    Summary The Wistar Institute (Wistar) is a biomedical research institute that carries out medical research and training. The institute performs research in the areas of cancer, infectious diseases, immunology and vaccine development. It also conducts research on genes, gene expression, and DNA biolo …
  • Calian Group Ltd (CGY):企業の財務・戦略的SWOT分析
    Summary Calian Group Ltd (CTL), formerly Calian Technologies Ltd, is a diversified company that offers professional services in the areas of health, training, information technology, engineering and manufacturing. The company’s health division offers occupational health and other clinical services s …
  • Smiths Group plc:戦略・SWOT・企業財務分析
    Smiths Group plc - Strategy, SWOT and Corporate Finance Report Summary Smiths Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Regulus Therapeutics Inc (RGLS):製薬・医療:M&Aディール及び事業提携情報
    Summary Regulus Therapeutics Inc (Regulus Therapeutics) is a biopharmaceutical company that discovers and develops microRNA based therapeutics. The company provides single stranded oligonucleotides, which are chemically synthesized chains of nucleotides that are mirror images of specific target micr …
  • e.l.f. Beauty, Inc. (ELF):企業の財務・戦略的SWOT分析
    e.l.f. Beauty, Inc. (ELF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • EKF Diagnostics Holdings Plc (EKF):企業の製品パイプライン分析
    Summary EKF Diagnostics Holdings Plc (EKF Diagnostics) is an in vitro diagnostics company that designs, develops, manufactures, and markets point-of-care (POC) devices and tests; and central laboratory products. Its POC range includes hemoglobin analyzers, glucose analyzers and HbA1c analyzers that …
  • Hdfc Bank Ltd
    Hdfc Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary Hdfc Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Capricor Therapeutics Inc (CAPR):企業の財務・戦略的SWOT分析
    Summary Capricor Therapeutics Inc (Capricor) is a biotechnology company that discovers, develops and commercializes biological therapeutics for the treatment of rare disorders. The company offers cardiac cell therapy and cenderitide products for the treatment of post myocardial infarction, advanced …
  • Otto Bock HealthCare GmbH-医療機器分野:企業M&A・提携分析
    Summary Otto Bock HealthCare GmbH (Otto Bock), a group company of Otto Bock Holding GmbH & Co. KG, is a medical device company that manufactures and distributes prosthetic and orthotic devices. It also offers mobility and seating solutions for the physically disabled adults and children. The product …
  • Hemisphere Energy Corp (HME):石油・ガス:M&Aディール及び事業提携情報
    Summary Hemisphere Energy Corp (Hemisphere), formerly Northern Hemisphere Development Corp is an oil and gas company that offers development of oil production reserves. The company offers strategic acquisitions and farm-ins that provide low-risk drilling opportunities. Its operations include heavy o …
  • Aptiv Plc:企業の戦略・SWOT・財務分析
    Aptiv Plc - Strategy, SWOT and Corporate Finance Report Summary Aptiv Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Aptiv PLC:企業の戦略・SWOT・財務情報
    Aptiv PLC - Strategy, SWOT and Corporate Finance Report Summary Aptiv PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Sientra Inc (SIEN):医療機器:M&Aディール及び事業提携情報
    Summary Sientra Inc (Sientra) is a medical device company that manufactures and markets plastic surgery implantable devices. The company’s products comprise breast implants, breast tissue expanders, silicone scar treatment and additional tissue expanders. It offers reconstructive surgery devices suc …
  • Cingulate Therapeutics LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Cingulate Therapeutics LLC (Cingulate) is a clinical stage biopharmaceutical company that develops new drug products for the treatment of attention deficit and hyperactivity disorder. The company’s pipeline products comprise CTX-1301 and CTX-1302 utilize precision timed release (PTR) drug de …
  • Ajinomoto Co Inc (2802):企業の財務・戦略的SWOT分析
    Ajinomoto Co Inc (2802) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Ahli Bank Qsc
    Ahli Bank Qsc - Strategy, SWOT and Corporate Finance Report Summary Ahli Bank Qsc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • The Tata Power Co Ltd (TATAPOWER):企業の財務・戦略的SWOT分析
    The Tata Power Co Ltd (TATAPOWER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Miromatrix Medical Inc-医療機器分野:企業M&A・提携分析
    Summary Miromatrix Medical Inc (Miromatrix Medical) is a life science company that develops regenerative medicines. The company offers MIRODERM biologic wound matrix, MIROMESH biologic matrix, liver function restoration, kidney products, diabetes treatment and cortical strut. It creates biological r …
  • Energias de Portugal SA (EDP)-石油・ガス分野:企業M&A・提携分析
    Summary Energias de Portugal, S.A. (EDP) is a vertically integrated power and gas utility that generates, transmits, distributes and sells electricity; and transports, distributes and sells natural gas. It produces electricity through a diversified portfolio of generation assets including wind, sola …
  • Shell Oman Marketing Co (SOMS):企業の財務・戦略的SWOT分析
    Summary Shell Oman Marketing Co (Shell Oman), formerly Shell Marketing (Oman) Ltd, is an oil and gas company that markets fuel and lubricants. The company provides engine oils and grease for cars, motorcycles and trucks. It also markets Shell automotive, aviation and marine products. Shell Oman owns …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆